Targeted drug combinations: avant-garde oncology

In this year’s most prominent oncology conferences, an emerging theme amongst leading abstracts was the increasing use of combination targeted therapy. Spurred by a presidential call for precision medicine, leading researchers are now exploring the use of a combination of targeted agents to simultaneously attack multiple cancer pathways. This strategy has been most exemplified in the case of cancer immunotherapy, as a number of groundbreaking studies in the clinical arena have demonstrated the promise and superiority of combination therapy.